R
RxREVU
Helps patients and providers save money on prescriptions by identifying the most effective medication at the best possible cost
About RxREVU
RxRevu operates in the healthcare technology sector, focusing on providing real-time prescription benefit data to healthcare providers. The company serves hospitals, health systems, and electronic health record (EHR) vendors across the United States. RxRevu's core product is a price transparency network that delivers patient-specific cost and coverage information at the point of care. This service helps healthcare providers make informed prescribing decisions, ultimately aiming to improve patient outcomes and reduce healthcare costs. The business model revolves around partnerships with healthcare organizations and EHR vendors, generating revenue through subscription fees and data-sharing agreements. By integrating its solution into native EHR workflows, RxRevu ensures that providers have seamless access to critical cost and coverage data during patient consultations. The company has been recognized for its rapid growth and innovation, as evidenced by its inclusion in the Inc. 5000 list of fastest-growing private companies.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 2013
- Headquarters
- Denver, United States
- Employees
- 43
- Open positions
- None listed
- Dealroom signal
- 62.4/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, Health Platform
- Sector
- Biotech & Life Sciences, Analytics, Predictive Analytics, Biotechnology, User Behavior, Neurology, Patient Care
- Technology
- Artificial Intelligence, Deep Tech, Machine Learning
- Business model
- SaaS
- Client focus
- b2b
- Investment activity
- 1 company, latest Mar 2026
- Capital deployed
- —
- Preferred round
- MERGER
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| MERGER✓Other financing | Mar 2026 | $0 | — | DoseSpot | ↗ |
| LATE VC✓Equity / VC | Jul 2021 | $8M | $80M | JAZZ Venture Partners | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for RxREVU is 240 monthly website visits, down 87.4% over the last three months. RxREVU's team declined 38.6% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
UnityPoint Health
UCHealth
Presbyterian Healthcare Services- JPJAZZ Venture Partners
Froedtert Health
Other known investors10 additional known investors
DoseSpot
Allumia Ventures
FirstTracks Ventures
Interra Health
MemorialCare Innovation Fund
Providence Ventures
Small Business Innovation Research
Summation Health Ventures
UnityPoint Health Ventures
Upslope Ventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about RxREVU on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See RxREVU’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.